Jeremy Chataway

Biography

Chataway is the clinical lead of the MS group at the NHNN (about 3000 patients) and was a member of the 2014 MS NICE panel. He has a particular interest in clinical trial design and was the Chief Investigator (CI) of the recently reported MS-STAT1 trial in secondary progressive MS, using high dose simvastatin; and is the CI of the currently recruiting MRC/EME MS-SMART trial, again in secondary progressive MS. He sits on the UK MS Society Grant Review Panel for Care and Services Research and UK MS Society Clinical Trials Network Steering Group; and is the Interim Clinical Director of the UCL Comprehensive Clinical Trials Unit. He is keen to facilitate both advanced trial design and implementation

Research Interest

Pathology